Efficacy and Safety of Bavituximab in Combination with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial

被引：0
|
作者：
Ali A. Mokdad
Hao Zhu
Muhammad S. Beg
Yull Arriaga
Jonathan E. Dowell
Amit G. Singal
Adam C. Yopp
机构：
[1] University of Texas Southwestern Medical Center,Department of Surgery, Division of Surgical Oncology
[2] University of Texas Southwestern Medical Center,Department of Medicine, Division of Medical Oncology
[3] University of Texas Southwestern Medical Center,Department of Medicine, Division of Digestive and Liver Diseases
来源：
Targeted Oncology | 2019年 / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：541 / 550
页数：9
相关论文
共 50 条
  • [31] A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancer
    Yang, Chunxu
    Sun, Shaoxing
    Xiang, Qingming
    Chen, Min
    Mei, Zijie
    Wu, Qiuji
    Qiu, Hui
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S290 - S290
  • [32] Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study
    Jiang, Yi
    Su, Ke
    Li, Han
    Wang, Chenjie
    Wu, Zhenying
    Chen, Jiali
    Zhang, Zhiyao
    He, Kun
    Han, Yunwei
    INVESTIGATIONAL NEW DRUGS, 2025, 43 (01) : 18 - 29
  • [33] Efficacy and safety of sintilimab plus XELOX as neoadjuvant therapy in patients with locally advanced gastric cancer: A single-arm open-label phase II trial.
    Guo, Honghai
    Ding, Ping'an
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Zhang, Ze
    Zheng, Tao
    Zhang, Zhidong
    Wang, Dong
    Tan, Bibo
    Zhao, Xuefeng
    Li, Yong
    Zhao, Qun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16091 - E16091
  • [34] An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma
    Mei, Qian
    Chen, Meixia
    Lu, Xuechun
    Li, Xiang
    Duan, Feng
    Wang, Maoqiang
    Luo, Guangbin
    Han, Weidong
    ONCOTARGET, 2015, 6 (18) : 16698 - 16711
  • [35] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial
    Wei, W.
    Ban, X.
    Yang, F.
    Huang, Y.
    Li, J.
    Cheng, X.
    Zheng, M.
    Li, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S762 - S762
  • [36] Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial
    Xu, Jianming
    Shen, Jie
    Gu, Shanzhi
    Zhang, Yun
    Wu, Lihua
    Wu, Jian
    Shao, Guoliang
    Zhang, Yanqiao
    Xu, Li
    Yin, Tao
    Liu, Jingfeng
    Ren, Zhenggang
    Xiong, Jianping
    Mao, Xianhai
    Zhang, Ling
    Yang, Jiayin
    Li, Lequn
    Chen, Xiaoming
    Wang, Zhiming
    Gu, Kangsheng
    Chen, Xi
    Pan, Zhanyu
    Ma, Kuansheng
    Zhou, Xinmin
    Yu, Zujiang
    Li, Enxiao
    Yin, Guowen
    Zhang, Xiao
    Wang, Shuni
    Wang, Quanren
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1003 - 1011
  • [37] Camrelizumab in combination with preoperative chemotherapy for locally advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study.
    Wang, Feng
    Qi, Yu
    Meng, Xiangrui
    Fan, Qingxia
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] A Phase II, Open-Label, Single Arm Trial to Assess the Efficacy and Safety of the Combination of Tisagenlecleucel and Ibrutinib in Mantle Cell Lymphoma (TARMAC)
    Minson, Adrian
    Hamad, Nada
    Butler, Jason P.
    Westerman, David Alan
    Ritchie, David
    Blombery, Piers
    Seymour, John F.
    Tam, Constantine S.
    Dickinson, Michael
    BLOOD, 2020, 136
  • [39] Clinical efficacy and safety of nivolumab in malignant non-pleural mesothelioma: A multicenter, open-label, single-arm, Japanese phase II trial (VIOLA) protocol
    Kuribayashi, Kozo
    Igeta, Masataka
    Daimon, Takashi
    Maede, Ibu
    Suna, Shinichiro
    Okamoto, Rika
    Kijima, Takashi
    ONCOLOGY, 2023, 101 (04) : 257 - 261
  • [40] Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: A single-arm, open-label, phase 2 trial
    Wei, Zhigong
    Zhu, Yuchun
    Cai, Lei
    Peng, Xingchen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345